Your AI-Trained Oncology Knowledge Connection!


Video

Dr. Backes on Pelvic Exenteration Surgery in Gynecologic Cancer

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses pelvic exenteration surgery for patients with gynecologic cancer.

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses pelvic exenteration surgery for patients with gynecologic cancer.

Pelvic exeneration is a rare procedure, explains Backes, as only 150 are done in the United States each year. This procedure removes all of the pelvic organs, which can cause a high-risk of complications and distant recurrence.

Some potential risk factors for recurrence include positive lymph nodes, lymphovascular invasion, perineural invasion, and tumor size. There are several studies suggesting that tumors greater than 3 cm increase the risk of a local and distant recurrence, and can decrease survival chances.

With this rare type of surgery, it is important to consult and counsel patients, according to Backes. Patients can undergo pelvic reconstruction after surgery.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute
Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Jordyn Silverstein, MD
Rachel N. Grisham, MD
Toon Van Gorp, MD, PhD
Matthew Wagar, MD of the University of Wisconsin School of Medicine and Public Health
Dr Salani on Novel Trial Designs and Therapies in Gynecologic Malignancies
Paul G. Richardson, MD
Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.